Wall Street bull Dan Ives says Apple iPhone production isn't feasible in the U.S.; Tim Cook to instead increase production in India by 60%

Apple may be getting ready to make a major shift in its global manufacturing strategy, and it's not in the direction US president Donald Trump wants, as per a report.
Apple May Shift 60% of iPhone Production to India
Wedbush analyst
Dan Ives
projected that the tech giant could ramp up its iPhone production in India to as much as 60% to 65% by this fall, depending on how ongoing
tariff negotiations
play out, according to Benzinga.
Analyst Says US Production Not an Option
In an X (formerly Twitter) post, he highlighted that the iPhone maker might significantly increase its
iPhone assembly
in India in a best-case scenario, but he also mentioned that Apple could revert to a China-driven iPhone strategy depending on the tariff situation and deal negotiations, as per Benzinga. However, he emphasized that "US iPhone production not feasible," as per his X post.
ALSO READ:
Joe Biden's doctor under the microscope: Dr. Kevin O'Connor faces tough questions amid fallout from ex-President's cancer news, did he fail to diagnose earlier?
Donald Trump Pushes Back Against Apple's India Expansion
Ives' remark comes after Trump recently expressed his disapproval of Apple's manufacturing expansion in India as he told Apple CEO
Tim Cook
, 'I don't want you building in India,' reported Benzinga.
Apple Reassures the Indian Government
However, even after Trump's rejection of the company's strategy, Apple is said to have reassured the Indian government of its commitment to its partnership with India as a major manufacturing hub, as per the report. Benzinga's government insiders have also pointed out that there is "no change" in the tech giant's investment plans in India, according to the report.
Live Events
ALSO READ:
With $258 billion in the black, U.S. Treasury posts historic surplus, experts say it might signal brighter days ahead
Apple Stock Reacts to Trade Developments
Meanwhile, Apple's stock recently rose after the trade negotiations between the United States and China because the firm is majorly dependent on a China-focused supply chain for manufacturing iPhones, as per Benzinga.
In the last five days, the shares of Apple increased 6.26%, however, on a year-to-date basis, the shares fell 13.29%, according to Benzinga Pro data.
FAQs
Is Apple moving away from China?
Not completely. It may still rely on China depending on how tariffs and negotiations go.
Why is Apple thinking of moving iPhone production to India?
To reduce risk. Apple wants to avoid depending too much on China, especially with rising tariffs and political tensions.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

India Today

37 minutes ago

• India Today

Israel-Iran conflict rages into second week as EU diplomacy fails to deliver

Israel and Iran traded strikes a week into their war on Friday as President Donald Trump weighed U.S. military involvement and key European ministers met with Iran's top diplomat in Geneva in a scramble to de-escalate the the first face-to-face meeting between Western and Iranian officials in the weeklong war concluded after four hours with no sign of an immediate give diplomacy a chance, Trump said he would put off deciding for up to two weeks whether to join Israel's air campaign against Iran. U.S. participation would most likely involve strikes against Iran's underground Fordo uranium enrichment facility, considered to be out of reach to all but America's 'bunker-buster' bombs. Whether or not the US joins, Israeli Prime Minister Benjamin Netanyahu said Israel's military operation in Iran would continue 'for as long as it takes' to eliminate what he called the existential threat of Iran's nuclear program and arsenal of ballistic missiles. Israel's top general echoed the warning, saying the Israeli military was ready 'for a prolonged campaign.'As negotiations ended in Switzerland, European officials expressed hope for future negotiations. Iran's top diplomat said he was open to further Foreign Minister Abbas Araghchi emphasized that Tehran had no interest in negotiating with the US while Israel continued attacking.'Iran is ready to consider diplomacy if aggression ceases and the aggressor is held accountable for its committed crimes,' he told date was set for the next round of previously agreed to limit its uranium enrichment and allow international inspectors access to its nuclear sites under a 2015 deal with the US, France, China, Russia, Britain and Germany in exchange for sanctions relief. But after Trump pulled the US unilaterally out of the deal during his first term, Iran began enriching uranium up to 60% — a short, technical step away from weapons-grade levels of 90% — and restricting access to its nuclear Israel said its warplanes hit dozens of military targets across Iran, including missile-manufacturing facilities, an Iranian missile crashed into Israel's northern city of Haifa, sending plumes of smoke billowing over the Mediterranean port and wounding at least 31 war between Israel and Iran erupted June 13, with Israeli airstrikes targeting nuclear and military sites, top generals and nuclear scientists. At least 657 people, including 263 civilians, have been killed in Iran and more than 2,000 wounded, according to a Washington-based Iranian human rights has retaliated by firing 450 missiles and 1,000 drones at Israel, according to Israeli army estimates. Most have been shot down by Israel's multitiered air defenses, but at least 24 people in Israel have been killed and hundreds RISE OVER THE PERILS OF ATTACKING IRAN'S NUCLEAR REACTORS Addressing an emergency meeting of the UN Security Council, the head of the International Atomic Energy Agency warned against attacks on Iran's nuclear reactors, particularly its only commercial nuclear power plant in the southern city of Bushehr.'I want to make it absolutely and completely clear: In case of an attack on the Bushehr nuclear power plant, a direct hit would result in a very high release of radioactivity to the environment,' said Rafael Grossi, chief of the U.N. nuclear watchdog. 'This is the nuclear site in Iran where the consequences could be most serious.'Israel has not targeted Iran's nuclear reactors, instead focusing its strikes on the main uranium enrichment facility at Natanz, centrifuge workshops near Tehran, laboratories in Isfahan and the country's Arak heavy water reactor southwest of the capital. Grossi has warned repeatedly that such sites should not be military initially reporting no visible damage from Israel's Thursday strikes on the Arak heavy water reactor, the IAEA on Friday said it had assessed 'key buildings at the facility were damaged,' including the distillation reactor was not operational and contained no nuclear material, so the damage posed no risk of contamination, the watchdog strikes on uranium enrichment facilities like Natanz can carry the risk of radiological contamination, experts say the chance of a serious incident is far lower than at reactors such as the Russian-built Bushehr power a call with Netanyahu, Russian President Vladimir Putin said he has secured Israel's promise to keep Russian workers at the plant out of harm's has long maintained its nuclear program is for peaceful it is the only non-nuclear-weapon state to enrich uranium up to 60%. Israel is widely believed to be the only Middle Eastern country with a nuclear weapons program but has never acknowledged it. Tune InMust Watch

Mint

37 minutes ago

• Mint

Four Indian pharma stocks that may be hit by US pharma tariff threat

Indian pharma stocks took a beating on Tuesday, 17 June, after US President Donald Trump said tariffs on pharmaceutical imports are coming 'very soon." His comments sent shockwaves across the market, dragging the Nifty Pharma index down by over 2% intraday. It was the worst-performing sector of the day. This isn't the first time Trump has hinted at such a move. He had dropped clues back in April, but this latest announcement has added urgency and concern. The Indian pharma industry, which relies heavily on exports to the US for generics and speciality drugs, is now facing concerns over potential revenue disruptions. Any disruption in trade or pricing could have a direct impact on revenues and margins. In this article, we take a look at five Indian pharmaceutical companies that could be the most affected by the proposed US tariffs. #1 Granules India Granules India has a presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It produces and supplies paracetamol, metformin, guaifenesin, and methocarbamol APIs. It has over 10 manufacturing facilities, approximately eight of which are located in India and two in the US. The company sells its products in global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific, and India. As per the FY24 annual report, 66% of Granules India's total revenue came from North America. This dependence has only deepened in recent quarters with the US market contributing 79% of revenue in the March 2025 quarter, according to the latest investor presentation. Data Source: Earnings Presentation FY25 and Q4 FY25 Given this significant exposure, any tariff-related cost increases could affect both the company's topline and margins. On 17 June 2025, executive director Priyanka Chigurupati said that the company is currently in the final stages of completing remediation work at its Gagillapur facility. It expects this process to wrap up in the next few months, after which a USFDA re-inspection is anticipated. Once this hurdle is cleared, Granules is aiming to launch 11 pending products in the US market, which were temporarily held back during the compliance phase. Production had been scaled down to prioritise remediation, but the company is now preparing to ramp up volumes again as operations stabilise. It's also working on its first major oncology product launch in the US, expected around FY28. To support its future growth strategy, the company is prepping its Genome Valley facility to meet upcoming USFDA and European audits. #2 Gland Pharma Gland Pharma has become a leader in generic injectables. Its presence spans 60 countries, including the US, Europe, Canada, and Australia. The company's business model primarily involves business-to-business, which contributes 98% of its revenue. It provides contract development, dossier compilation, and technology transfer services. The balance comes from business to consumer. Geographically, the company has a strong presence in the US, which contributes 54% of its revenue. Its revenue in the region has grown from ₹2,585 crore in FY22 to ₹3,037 crore in FY24. This makes the company vulnerable to tariffs. Recently, Gland Pharma received approval from the US Food and Drug Administration (US FDA) for Angiotensin II Acetate Injection. Since the company is the first to submit for exclusivity, it qualifies for 180 days of exclusivity for the generic drug. #3 Aurobindo Pharma Aurobindo Pharma has built a strong presence across more than 150 countries, manufacturing generic formulations, APIs, and injectables. It's the largest generic drug company in the US and ranks among the top 10 generic players in eight European countries. That's where the concern comes in. According to its FY24 annual report, half (48%) of Aurobindo's revenue comes from the US. Data Source: Aurobindo Pharma Annual Report 2023-24 As per the company's investor presentation in March 2025, it holds the top spot in the US in terms of oral solids prescription volume, commanding a 10.5% market share in the September 2024 quarter. So, when talk of new US tariffs on pharma imports hits the headlines, Aurobindo's heavy exposure naturally makes the stock vulnerable to a fall. On 16 June 2025, the company announced the incorporation of a new wholly owned subsidiary, Cresedemo Pharma LLC, in the US. This move aims to further strengthen its US pharma business. While the new entity signals Aurobindo's long-term commitment to the US market, the proposed tariffs could present near-term headwinds for the company. Looking ahead, Aurobindo is placing a big bet on the future of biosimilars. With 14 promising products currently in the pipeline, the company is eyeing a massive US$ 50 bilion+ market opportunity. If things go as planned, this could open up an exciting new growth path and offer some much-needed cushion against any potential policy shocks like the proposed US tariffs. Also Read: India seeks financial details of pharmaceutical marketing practices, industry caught in a bind #4 Dr Reddy's Laboratories Dr Reddy's Lab is one of India's largest pharmaceutical firms in the country. The company manufactures a wide range of pharmaceuticals with expertise spanning several therapeutic areas. Through its step-down subsidiary Aurigene Pharmaceutical Services Ltd (APSL), it's making strong strides in the CDMO space. APSL acts as a comprehensive Contract Research, Development, and Manufacturing Organization (CRO/CDMO), offering end-to-end solutions to global pharmaceutical and speciality companies. It has cGMP manufacturing facilities in the UK, Mexico, USA, and India, enabling it to serve a global clientele. Despite this global footprint, a large chunk of Dr Reddy's revenue still comes from the US. Also, the latest investor presentation of Q4FY25, shows 42% of the total revenue from the US market. This heavy dependence on the US leaves the company exposed to the potential impact of new tariffs. In response to increasing tariff speculation, the company has indicated a desire to consider local manufacturing in the US, through acquisitions. This will not only help reduce the risk of import duties but will also deepen its foot in one of its most important markets. Meanwhile, Dr Reddy focuses on maintaining its growth. The company plans to launch 15-20 new products in the US every year. Also Read: Dr. Reddy's focused on securing supply chains amid US tariff uncertainty Conclusion While the possibility of imports has rattled the sector, it's important to take a balanced view before making investment decisions. There's no denying that companies with high revenue exposure to the US, like Aurobindo Pharma, Granules India, and Dr Reddy's could face near-term challenges if such tariffs are implemented. Margins may come under pressure and growth plans might require changes. However, the long-term fundamentals of India's pharmaceutical industry remain strong. The government is actively supporting the sector through key initiatives such as the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, Promotion of Bulk Drug Parks, Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS), and the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), which aims to make quality medicines accessible at affordable prices. Moreover, according to a recent EY-FICCI report, the Indian pharmaceutical market is poised to reach a value of around $130 billion by 2030, signalling strong growth potential. It's important to conduct thorough research on financials and corporate governance before making investment decisions, ensuring they align with your financial goals and risk tolerance. Happy Investing. Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. This article is syndicated from

Hans India

an hour ago

• Hans India

Strong demand, stable activity in economy

India's economic indicators are becoming more supportive of growth, according to the report released by Motilal Oswal Private Wealth (MOPW) on Friday. The report highlights that several positive trends are emerging on the domestic front, including higher GDP growth, easing inflation, and strong tax GDP grew by 7.4 per cent in the fourth quarter of FY25, which is the highest reading in the last four has remained below 4 per cent for four consecutive months, and GST collections have been rising steadily. These signs indicate strong demand and stable activity in the formal sector of the report also notes that India's policy environment is now moving in a unified direction. Fiscal, monetary, and regulatory policies are all aimed at maintaining growth increased tax exemption limits that came into effect from April 2025 are expected to improve disposable incomes and boost the same time, the government's capital expenditure continues to rise, supporting the investment the global front, the environment remains mixed. In April and May, markets faced worries over tariffs and geopolitical tensions. However, the situation improved with a delay in global tariff implementation and a ceasefire announcement between India and Pakistan. This improved global sentiment has helped global equity markets, with the MSCI World Index reaching record highs. Meanwhile, rising bond yields in Japan and China's shift towards gold show that global investors are moving away from US could become a concern as the US faces refinancing of $9 trillion in debt this a weaker Dollar Index could help emerging markets like India by attracting more foreign investments. In the Indian stock market, valuations have increased as earnings have not grown at the same Nifty-50's one-year forward valuation has risen above its long-term average, and mid and small-cap stocks continue to trade at a premium. This makes careful stock selection and active management more important for investors looking to generate higher returns, the report stated.